BioAffinity Cost Of Revenue vs Research Development Analysis

BIAFW Stock

USD 0.72 0.03 4.00%

BioAffinity Technologies financial indicator trend analysis is way more than just evaluating BioAffinity Technologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioAffinity Technologies is a good investment. Please check the relationship between BioAffinity Technologies Cost Of Revenue and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Cost Of Revenue vs Research Development

Cost Of Revenue vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioAffinity Technologies Cost Of Revenue account and Research Development. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between BioAffinity Technologies' Cost Of Revenue and Research Development is -0.39. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Research Development in the same time period over historical financial statements of bioAffinity Technologies Warrant, assuming nothing else is changed. The correlation between historical values of BioAffinity Technologies' Cost Of Revenue and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of bioAffinity Technologies Warrant are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Cost Of Revenue i.e., BioAffinity Technologies' Cost Of Revenue and Research Development go up and down completely randomly.

Correlation Coefficient

-0.39

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on BioAffinity Technologies income statement and represents the costs associated with goods and services BioAffinity Technologies provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Research Development

Most indicators from BioAffinity Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioAffinity Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

At this time, BioAffinity Technologies' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to climb to about 7.1 M in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.0M	2.5M	37.1K	35.3K
Depreciation And Amortization	4.8K	10.2K	249.6K	262.1K

Interest Expense Depreciation And Amortization

BioAffinity Technologies fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Non Current Liabilities Total	Inventory	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.55	-0.08	-0.51	0.78	0.56	-0.85	-0.8	0.81	0.92	0.53	-0.47	0.92	0.51	-0.54	1.0	0.97	-0.33	0.95	-0.57	0.95	0.81	-0.98	-0.5	0.98	0.56
Short Long Term Debt Total	-0.55		0.81	1.0	-0.95	-0.43	0.86	0.26	-0.27	-0.49	-0.41	0.37	-0.49	-0.4	0.34	-0.53	-0.5	0.93	-0.51	1.0	-0.56	-0.11	0.6	0.81	-0.57	-0.43
Other Current Liab	-0.08	0.81		0.84	-0.61	-0.01	0.53	-0.27	0.2	-0.09	0.0	0.05	-0.09	0.01	0.11	-0.06	0.0	0.91	-0.08	0.78	-0.09	0.45	0.12	0.83	-0.08	0.0
Total Current Liabilities	-0.51	1.0	0.84		-0.93	-0.42	0.83	0.23	-0.24	-0.45	-0.4	0.34	-0.45	-0.39	0.31	-0.48	-0.46	0.94	-0.46	0.99	-0.52	-0.07	0.56	0.82	-0.53	-0.41
Total Stockholder Equity	0.78	-0.95	-0.61	-0.93		0.55	-0.96	-0.52	0.5	0.72	0.52	-0.49	0.72	0.5	-0.5	0.77	0.73	-0.8	0.74	-0.95	0.76	0.4	-0.81	-0.77	0.8	0.55
Property Plant And Equipment Net	0.56	-0.43	-0.01	-0.42	0.55		-0.39	-0.86	0.81	0.28	1.0	0.05	0.28	1.0	-0.05	0.52	0.69	-0.12	0.35	-0.5	0.73	0.61	-0.7	-0.26	0.65	1.0
Net Debt	-0.85	0.86	0.53	0.83	-0.96	-0.39		0.49	-0.47	-0.86	-0.35	0.62	-0.86	-0.33	0.64	-0.85	-0.75	0.73	-0.87	0.86	-0.76	-0.44	0.83	0.75	-0.85	-0.39
Retained Earnings	-0.8	0.26	-0.27	0.23	-0.52	-0.86	0.49		-0.91	-0.63	-0.85	0.22	-0.63	-0.84	0.35	-0.79	-0.87	-0.08	-0.67	0.32	-0.85	-0.87	0.87	0.17	-0.86	-0.87
Accounts Payable	0.81	-0.27	0.2	-0.24	0.5	0.81	-0.47	-0.91		0.55	0.8	0.01	0.55	0.79	-0.07	0.78	0.93	-0.02	0.62	-0.33	0.93	0.89	-0.87	-0.23	0.8	0.81
Cash	0.92	-0.49	-0.09	-0.45	0.72	0.28	-0.86	-0.63	0.55		0.25	-0.7	1.0	0.23	-0.79	0.95	0.81	-0.31	1.0	-0.49	0.77	0.66	-0.85	-0.47	0.91	0.29
Non Current Assets Total	0.53	-0.41	0.0	-0.4	0.52	1.0	-0.35	-0.85	0.8	0.25		0.08	0.25	1.0	-0.02	0.49	0.67	-0.11	0.31	-0.48	0.7	0.59	-0.68	-0.23	0.62	1.0
Non Currrent Assets Other	-0.47	0.37	0.05	0.34	-0.49	0.05	0.62	0.22	0.01	-0.7	0.08		-0.7	0.09	0.82	-0.5	-0.3	0.29	-0.66	0.35	-0.23	-0.31	0.36	0.07	-0.5	0.05
Cash And Short Term Investments	0.92	-0.49	-0.09	-0.45	0.72	0.28	-0.86	-0.63	0.55	1.0	0.25	-0.7		0.23	-0.79	0.95	0.81	-0.31	1.0	-0.49	0.77	0.66	-0.85	-0.47	0.91	0.29
Net Receivables	0.51	-0.4	0.01	-0.39	0.5	1.0	-0.33	-0.84	0.79	0.23	1.0	0.09	0.23		0.0	0.47	0.65	-0.1	0.29	-0.46	0.69	0.59	-0.66	-0.22	0.6	1.0
Common Stock Shares Outstanding	-0.54	0.34	0.11	0.31	-0.5	-0.05	0.64	0.35	-0.07	-0.79	-0.02	0.82	-0.79	0.0		-0.59	-0.36	0.17	-0.74	0.33	-0.31	-0.24	0.48	0.34	-0.63	-0.06
Other Current Assets	1.0	-0.53	-0.06	-0.48	0.77	0.52	-0.85	-0.79	0.78	0.95	0.49	-0.5	0.95	0.47	-0.59		0.95	-0.31	0.97	-0.55	0.93	0.8	-0.97	-0.5	0.98	0.53
Other Stockholder Equity	0.97	-0.5	0.0	-0.46	0.73	0.69	-0.75	-0.87	0.93	0.81	0.67	-0.3	0.81	0.65	-0.36	0.95		-0.26	0.86	-0.54	0.99	0.87	-0.98	-0.44	0.95	0.7
Total Liab	-0.33	0.93	0.91	0.94	-0.8	-0.12	0.73	-0.08	-0.02	-0.31	-0.11	0.29	-0.31	-0.1	0.17	-0.31	-0.26		-0.32	0.91	-0.32	0.12	0.34	0.77	-0.3	-0.12
Total Current Assets	0.95	-0.51	-0.08	-0.46	0.74	0.35	-0.87	-0.67	0.62	1.0	0.31	-0.66	1.0	0.29	-0.74	0.97	0.86	-0.32		-0.52	0.82	0.7	-0.89	-0.48	0.94	0.36
Short Term Debt	-0.57	1.0	0.78	0.99	-0.95	-0.5	0.86	0.32	-0.33	-0.49	-0.48	0.35	-0.49	-0.46	0.33	-0.55	-0.54	0.91	-0.52		-0.6	-0.16	0.63	0.8	-0.6	-0.49
Common Stock	0.95	-0.56	-0.09	-0.52	0.76	0.73	-0.76	-0.85	0.93	0.77	0.7	-0.23	0.77	0.69	-0.31	0.93	0.99	-0.32	0.82	-0.6		0.83	-0.98	-0.51	0.93	0.73
Long Term Debt	0.81	-0.11	0.45	-0.07	0.4	0.61	-0.44	-0.87	0.89	0.66	0.59	-0.31	0.66	0.59	-0.24	0.8	0.87	0.12	0.7	-0.16	0.83		-0.79	0.05	0.78	0.62
Non Current Liabilities Total	-0.98	0.6	0.12	0.56	-0.81	-0.7	0.83	0.87	-0.87	-0.85	-0.68	0.36	-0.85	-0.66	0.48	-0.97	-0.98	0.34	-0.89	0.63	-0.98	-0.79		0.55	-0.98	-0.71
Inventory	-0.5	0.81	0.83	0.82	-0.77	-0.26	0.75	0.17	-0.23	-0.47	-0.23	0.07	-0.47	-0.22	0.34	-0.5	-0.44	0.77	-0.48	0.8	-0.51	0.05	0.55		-0.51	-0.25
Net Invested Capital	0.98	-0.57	-0.08	-0.53	0.8	0.65	-0.85	-0.86	0.8	0.91	0.62	-0.5	0.91	0.6	-0.63	0.98	0.95	-0.3	0.94	-0.6	0.93	0.78	-0.98	-0.51		0.65
Property Plant And Equipment Gross	0.56	-0.43	0.0	-0.41	0.55	1.0	-0.39	-0.87	0.81	0.29	1.0	0.05	0.29	1.0	-0.06	0.53	0.7	-0.12	0.36	-0.49	0.73	0.62	-0.71	-0.25	0.65

Click cells to compare fundamentals

BioAffinity Technologies Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioAffinity Cost Of Revenue vs Research Development Analysis

Cost Of Revenue vs Research Development

Cost Of Revenue vs Research Development Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Research Development

BioAffinity Technologies fundamental ratios Correlations

BioAffinity Technologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for BioAffinity Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Net Receivables	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Net Invested Capital	- 0.98	Non Current Liabilities Total
Non Current Liabilities Total	- 0.98	Common Stock
Non Current Liabilities Total	- 0.98	Other Stockholder Equity
Non Current Liabilities Total	- 0.98	Total Assets
Non Current Liabilities Total	- 0.97	Other Current Assets
Net Debt	- 0.96	Total Stockholder Equity